Importantly, over half of metastatic sites demonstrated expression of HER2 and HER3 with stromal expression of ASPN, suggesting this signaling mechanism may have critical roles in metastatic prostate cancer. Here, ERBB2 is linked to metastatic prostate carcinoma.